FDA Enforcement Letters Should Be Required Reading for Every Pharma Marketer

FDA enforcement letters may be one of the best sources of free marketing intelligence available to drug companies. They tell marketers what the FDA is looking at, what the agency believes is misleading and, perhaps most importantly, how the FDA is interpreting the messages patients and physicians actually take away from drug promotion. And right now, marketers should be paying very close attention.

The FDA dramatically increased the pressure on drug promotion beginning in 2025. In September 2025, the agency announced that it was sending thousands of letters to pharmaceutical companies and issuing roughly 100 cease-and-desist letters aimed at deceptive drug advertising.

By mid-July 2026, FDA’s Office of Prescription Drug Promotion had already posted roughly 20 Untitled Letter actions involving products from companies including Pfizer, Novo Nordisk, Bayer, Sanofi, Viatris, Lundbeck, Incyte, Alnylam and others. That’s not background noise. It’s data.

Stop Asking “Is the Claim Accurate?”

The worst error pharma marketers make is believing promotional compliance hinges on whether a claim, sentence or statement is technically true. It doesn’t. The FDA frequently looks at the overall impression left by the communication. That’s a much tougher standard to meet. The words themselves might be technically accurate. The clinical data may indeed back up what’s said in that sentence. But what does that leave the patient thinking after they see the ad? What about the physician who reviews the chart? When you take the headline, image, graph, and footnote together, what conclusion does your audience reach? Marketers stumble here. The FDA isn’t asking if each sentence can stand alone and be defended. The Agency is asking if the overall message leaves a false impression. There’s a big difference.

The Word Pharma Marketers Should Fear Is “Implies”

Pharma marketing organizations spend countless hours arguing over individual words during MLR review. But sometimes the greatest regulatory risk is not what the ad says. It’s what the ad implies. A headline can imply.

An image can imply. A graph can imply. Two statistics placed next to each other can imply. Even facts, when presented a certain way, can paint an inaccurate picture. That’s why we, as marketers, need to think about claims not as stand-alone sentences. Consumers don’t see ads that way. Physicians don’t read ads that way either. They see the whole message. FDA does too.

Enforcement Letters Are Marketing Case Studies

When you review recent enforcement actions, however, another trend becomes clear. FDA isn’t just policing traditional pharma advertising. It’s policing the entire promotional universe. Websites. TV. YouTube. Instagram. Podcasts. HCP communications. Social media. Heck, even communication by company executives and other affiliated individuals. Earlier this year, in May 20 25, the FDA issued a Warning Letter to Sprout Pharmaceuticals concerning an Instagram post about ADDYI that appeared on the personal account of CEO Cindy Eckert.

The Agency said the post included efficacy claims with limited risk information and failed to include material information about the indication and limitations of use. Here’s the takeaway: Just because your pharma brand has an awesome corporate website doesn’t mean your promotional footprint ends there. These days you have CEOs posting on LinkedIn, executives guest starring on podcasts, physicians partnering with brands, social influencers talking about diseases and treatment options, paid social campaigns, patient ambassadors, third-party content partners, and more.

Fixing One Ad Isn’t Enough

This has been really bugging me: The ImmunityBio ANKTIVA situation. FDA sent an Untitled Letter in January 20 on promotional webpages. But then, in March, FDA sent a Warning Letter on a DTC tv advertisement and podcast that specifically called out previous concerns about promotion of the product. Pharma companies take note: When FDA complains about a promotional concept, it’s not just that single execution that needs to be fixed. Where else is that idea showing up? Website? Sales aid? Speaker deck? Patient materials? Social posts? Paid search? PR? Congressional materials? Executive interviews? The problem isn’t necessarily the webpage. The problem may be the underlying promotional strategy. That’s a completely different kettle of fish.

Pharma Spends Millions on Competitive Intelligence. FDA Gives Some of It Away for Free..

Here’s what puzzles me. Pharma marketers spend millions of dollars on market research, competitive intelligence and consultants. The FDA is sending them dossiers telling them exactly what promotional activities it doesn’t like.

Why aren’t pharma marketers pouring over them? If I’m responsible for marketing an oncology product, I care about every material enforcement action involving the promotion of an oncology product. If I’m planning a DTC campaign, I want to know about recent DTC enforcement actions. If my promotional strategy involves comparative efficacy claims, I care about how the FDA has viewed comparative claims. If we plan to use social media, influencers, podcasts, or company executives, I want to know what the FDA has challenged in those venues. Throw it all in a database. Track Product. Therapeutic area. Audience. Channel. Claim. Level of evidence. FDA objection. Result. Find patterns. Suddenly FDA enforcement actions stop being a bunch of PDFs and start being marketing intelligence.

AI Makes This Even More Valuable

Okay, here’s another AI opportunity. How about creating an internal search engine loaded with years of FDA promotional enforcement actions? FDA promosquizzes anyone? You could search for: “Oncology promotions that were questioned for efficacy statements” “Enforcement actions citing subgroup analyses” “Search for problems with risk presentation in Facebook posts” “Examples of FDA pushing back on endpoints or clinical-trial results” “Repeat promotional problems in Direct to Consumer ads” Yeah, that would be a lot more useful than another useless annual compliance training session. We all know marketers shouldn’t make misleading claims. But we need to see how marketing messages that sound reasonable can become problematic when viewed by the FDA. Now that’s something we can act on.

Don’t Let Regulatory Intelligence Kill Good Marketing

But there’s another side to that. The lesson of the enforcement letters should not be that pharma marketers have to become even more risk-averse. Pharma has enough dull advertising already. The goal shouldn’t be marketing that’s so squeaky clean no one notices it. The goal should be knowing precisely what the evidence supports marketers saying — and saying it as powerfully as you can. There’s a big difference between compliant marketing and scared marketing. Good marketers should be fighting for differentiation. Regulatory should be defining the parameters. Medical should be ensuring the science is rock solid. Legal should be evaluating risk. But the end goal should still be effective marketing. Otherwise, what’s the point?

MLR Needs to Get Involved Earlier

Another issue that enforcement letters highlight: too many pharma companies treat MLR as the “finish line.” Marketing comes up with a plan. The creative team comes up with materials. Everyone gets excited about the new campaign. Then the materials are sent for review. Reverse that process. By the time something is in review, everyone is emotionally and financially committed to making it work. Regulatory intelligence should be considered during development of the creative brief. Before embarking on a campaign, ask yourself:

What has FDA recently challenged in this therapeutic area?

What types of efficacy claims is the FDA currently challenging?

What channels is FDA currently challenging?

What claims against competitors are being challenged?

How is FDA defining consumer takeaway?

What errors have competitors already made?

And one question no one thinks to ask: What claims has FDA not challenged?

Knowing the answers to these questions can help you identify opportunities as well as restrictions. Enforcement intelligence shouldn’t just tell you where you can’t go. It should help you figure out where you can go.

The Regulatory Environment Has Changed

For many years we’ve had individuals in pharma who have looked at the relatively low number of OPDP enforcement letters each year and assumed that promotional enforcement was not a significant risk. That assumption has always been risky. It’s considerably riskier now. Given FDA’s expected 2025 crackdown and the enforcement actions we’ve already seen this year, marketers should rethink their risk exposure. Not panic. Just pay attention. History is not necessarily a guide to future enforcement activity. Brands being managed today based on assumptions from five or ten years ago are at risk of making a very costly mistake.

Pharma Marketers Need to Start Reading the Letters

FDA enforcement letters should not collect dust in Regulatory Affairs. They should be discussed in brand team meetings. Agencies should review them. Medical Affairs should dissect them. Competitive intelligence groups should categorize them.

Senior marketers should look for trends. Every enforcement letter provides the answer to a valuable question: What did a fellow pharma marketer think it could say that FDA didn’t think it could? That’s insight worth learning. Especially when you realize that there’s more to learn from each letter than just what was taken down. Why was it taken down? Was the data they used not supportive enough? Was the claim too broad? Did they oversimplify or minimize risk? Did they make a comparison that wasn’t really fair? Did the graphics and creative imply a takeaway that was never actually stated outright?

Pharma marketers can use those lessons to improve their marketing. Not just safer. But better. And it’s the companies that take the time to understand why FDA enforcements occur that will benefit the most. They won’t simply play it safer; they’ll become far smarter about risk. That’s the opportunity. The FDA is giving us case studies about what works (and doesn’t) in pharma marketing for free. So why should pharma marketers be reading enforcement letters? Isn’t the real question why aren’t they reading them already?

About Richard Meyer

I’m Richard Meyer — a 25 year healthcare marketing strategist and writer focused on the intersection of direct-to-consumer marketing, healthcare economics, and human behavior.I started Work of DTC Marketing because too much of the conversation around pharma and healthcare marketing is either overly promotional, overly technical, or completely disconnected from how the system actually works.Here, I write about what DTC really does, how incentives drive behavior inside healthcare organizations, why patients are often treated like revenue streams instead of people, and why “best practices” are frequently just recycled assumptions.My background spans digital marketing, public relations, and healthcare strategy, and my approach is pragmatic, skeptical of hype, and grounded in data and lived experience. I’m less interested in what sounds good in a deck and more interested in what actually changes outcomes — for companies, doctors, and especially patients.

View all posts by Richard Meyer →

Leave a Reply